MedPath
HSA Approval

CONJUPRI TABLETS 5MG

SIN17153P

CONJUPRI TABLETS 5MG

CONJUPRI TABLETS 5MG

December 26, 2024

LOTUS INTERNATIONAL PTE. LTD.

Regulatory Information

HSA regulatory responsibility and product classification details

Regulatory Responsibility

RegistrantLOTUS INTERNATIONAL PTE. LTD.

Product Classification

D
Drug Type
Therapeutic
F
Forensic Class
Prescription Only
HSA Singapore Classification

Formulation Information

TABLET

ORAL

Medical Information

C08CA17

Manufacturer Information

LOTUS INTERNATIONAL PTE. LTD.

CSPC Ouyi Pharmaceutical Co., Ltd.

Active Ingredients

Levamlodipine maleate eqv. levamlodipine

5.00 mg

Levamlodipine

Documents

Package Inserts

Conjupri Tablets PI.pdf

Approved: December 26, 2024

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

CONJUPRI TABLETS 5MG - HSA Approval | MedPath